Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: neurodegenerative disorders immunotherapeutics and diagnostics - ProMIS Neurosciences

Next Previous
X
Search
Drug Profile

Research programme: neurodegenerative disorders immunotherapeutics and diagnostics - ProMIS Neurosciences

Alternative Names: Amorfix EP-AD; Disease specific epitope (DSE) monoclonal antibodies; Neurodegenerative disorders monoclonal antibodies - Amorfix Life Sciences; Neurodegenerative disorders vaccines - Amorfix Life Sciences

Latest Information Update: 28 Jan 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amorfix Life Sciences
  • Developer ProMIS Neurosciences; University of British Columbia
  • Class Diagnostic agents; Vaccines
  • Mechanism of Action Immunomodulators; Superoxide dismutase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Neurodegenerative disorders

Highest Development Phases

  • Suspended Creutzfeldt-Jakob disease
  • No development reported Alzheimer's disease; Amyotrophic lateral sclerosis

Most Recent Events

  • 28 Jan 2021 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis(Diagnosis) in Canada (Parenteral)
  • 28 Apr 2019 No recent reports of development identified for preclinical development in Alzheimer's-disease(Diagnosis) in Canada (Parenteral, Injection)
  • 28 Mar 2017 Preclinical development in Amyotrophic lateral sclerosis and Alzheimer's disease is ongoing in Canada

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top